News
Actelion obtains an option vamorolone from ReveraGen
Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.
ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA
ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy
Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be
More >ReveraGen BioPharma Receives $3M for Phase 2 Studies of Vamorolone in Duchenne
PPMD is thrilled to see the continued progress of VBP-15, now known as Vamorolone. Progress to date includes a first in-human study of healthy volunteers and animal data which suggests it has none of the side effects of steroids, does
More >